Contraceptive Pills Market: Global Industry Analysis and Forecast (2024-2030)

  • Contraceptive Pills Market size was valued at USD 20.91 Bn. in 2023 and the total Contraceptive Pills Market size is expected to grow at a CAGR of 5.54% from 2024 to 2030, reaching nearly USD 30.49 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2061

Contraceptive Pills Market Overview

Contraceptive pills, commonly referred to as birth control pills, are oral medications designed to prevent pregnancy. These pills generally contain synthetic hormones, either a combination of estrogen and progesterone or just progesterone. By regulating the menstrual cycle and preventing ovulation, it offers a reliable method of contraception.

 

The report employed a bottom-up methodology to determine market sizes at both global and regional levels. Additionally, a SWOT analysis was performed to identify the strengths and weaknesses of key players in the Contraceptive Pills sector. To ensure the accuracy of its findings, the report combined both primary and secondary research methods. Primary research included distributing surveys, administering questionnaires, and conducting phone interviews with industry experts, leaders, marketers, and entrepreneurs in the Contraceptive Pills market.

 

The Contraceptive Pills Market report provides a comprehensive analysis of the strategies employed by top companies and a detailed examination of market segments and regional trends. It offers critical insights into pricing, costs, revenues, and profit margins, making it an invaluable resource for investors in this sector. By analyzing market dynamics, the report assesses the drivers of growth, potential constraints, opportunities, and challenges across different regions and segments.

 

Female sterilization is the most commonly used contraceptive method globally (23 percent of contraceptive users), followed by male condoms (22 percent). Each of these methods has more than 200 million users 219 million for female sterilisation and 208 million for male condoms.

Contraceptive Pills Market

 

To get more Insights: Request Free Sample Report

 

Contraceptive Pills Market Dynamics

Factors Driving the Growth of the Contraceptive Pills Market

The surge in contraception pills, as it depends on perceptions of motherhood, the likelihood and implications of pregnancy, and perceived side effects and health risks, has boosted the market growth. The rise in women’s choices is influenced by partners, family, peers, health care providers, and wider society, and their knowledge and capacity to make decisions has propelled the market growth. Contraceptive pill choice is also influenced by the characteristics of methods, particularly the ease of use, invasiveness, discreteness, and impact on intimacy and the characteristics of services, including accuracy of information provided, convenience, confidentiality, costs, and the attitudes and behavior of healthcare professionals.

 

The rise in the demand for the prevention of unintended pregnancies helps to lower maternal ill-health and the number of pregnancy-related deaths has driven the contraceptive pill market growth. Additionally, the lack of interest by big pharma comes at a time when scientific and technological advances in biology and medicine are creating more opportunities than ever for the development of new and innovative drug products has influenced market growth. Doctors and prescribers are seeing an increase in demand for different forms of contraception, including emergency contraception and longer-lasting forms of birth control has escalated the Contraceptive Pills market demand.

Contraceptive Pills Market1

Challenges and Barriers in the Contraceptive Pills Market

 The contraceptive Pills Market has faced several challenges as there is a slower adoption rate of contraceptive pills in many regions and limited access to services among the young, poorer, and unmarried people has restrained the contraceptive pills market growth.  As these barriers are addressed in some regions there have been increases in demand satisfied with modern methods of contraception. The increased dosage of contraceptive pills has caused various side effects such as nausea, weight gain, mood changes, and increased risk of blood clots has been hindering the market growth. These potential health risks have deterred users and led to negative perceptions.

 

Additionally, the availability of cheaper generic versions of branded contraceptive pills puts pressure on profit margins and market share for the original manufacturer. In many developing countries, access to contraceptive pills is limited due to poor healthcare infrastructure, lack of awareness, and socio-economic barriers. Contraceptive pills need to pass through rigorous regulatory approvals before it have been marketed and the process is time-consuming and expensive, often involving extensive clinical trials to prove efficacy and safety.

 

  • The proportion of women of reproductive age (aged 15–49 years) who have their need for family planning satisfied with modern methods (SDG indicator 3.7.1) is 77.5% globally in 2022, an increase of 10 percentage points since 1990 (67%) (2).

 

Contraceptive Pills Market Segment Analysis

Based on Type, the Combination Pills segment dominated the market and is expected to maintain its dominance through the forecast period with an increasing CAGR. The Contraceptive pills market has seen significant growth thanks to the increased use of combination pills that contain both estrogen and progestin. These pills are effective at preventing pregnancy by preventing ovulation, increasing cervical mucus thickness, and thinning the uterine lining. This makes it difficult for sperm to reach the uterus and for a fertilized egg to implant, leading to their popularity in the market.

 

In addition, combination pills containing estrogen can also help reduce acne by lowering androgen levels that trigger oil secretion in the skin. They have also been found to reduce the occurrence of ovarian cysts and lower the risk of ovarian and endometrial cancers. Healthcare professionals and patients have relied on these pills for many years due to their proven safety and efficacy. Their extensive inclusion in insurance plans across numerous areas provides increased access and affordability for a greater number of people. A lot of women discover that it is simple to integrate the daily habit of taking a pill into their daily lives. The additional advantages aside from preventing pregnancy make combination pills a favored option for women looking for birth control.

 

Contraceptive Pills Market Regional Analysis

North America dominated the market and is expected to dominate the market with an increasing CAGR through the forecast period. In North America, the Contraceptive pill market has seen significant growth thanks to the increased use of combination pills that contain both estrogen and progestin has boosted the market growth in the region. These pills are highly effective in preventing pregnancy by preventing ovulation, thickening cervical mucus, and thinning the uterine lining, making it difficult for sperm to reach the uterus and a fertilized egg to implant resulting in the higher demand for the contraceptive pills market in the region.  

 

Combination pills have been trusted by healthcare professionals and patients for their safety and effectiveness for many years in the region. In the United States and Canada, easily accessible comprehensive sex education programs educate individuals on the benefits and proper usage of various contraceptive methods, including pills. This results in a well-informed population that is more likely to use contraceptives effectively. The healthcare system in the region is well-established, ensuring widespread availability of contraceptives through pharmacies, clinics, and healthcare providers. Government programs and NGOs actively promote family planning and contraceptive use, with organizations like Planned Parenthood in the U.S. offering education, resources, and access to contraception.

 

  • The birth control pill is the most commonly prescribed form of contraception in the US. Approximately 25% of women aged 15 to 44 who currently use contraception reported using the pill as their method of choice.

Contraceptive Pills Market2

Contraceptive Pills Market Competitive Landscape

  • In 2024, Teva Pharmaceuticals and mAbxience announced a major strategic licensing deal for a biosimilar candidate dedicated to numerous areas of oncology. Currently in development, the collaboration aims to cover various markets, such as the United States and Europe. Teva’s collaboration with Alvotech on Simlandi (adalimumab-risk), an interchangeable high-concentration, citrate-free biosimilar to Humira, was given FDA approval.
  • In July 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that the U.S. Food and Drug Administration (FDA) approved Opill, a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages. Opill is the first-ever birth control pill available over the counter in the United States.
  • In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for USD 229 in cash per share, for a total enterprise value of approximately USD 43 billion.

Contraceptive Pills  Market Scope

Market Size in 2023

USD 20.91 Bn.

Market Size in 2030

USD 30.49 Bn.

CAGR (2024-2030)

5.54 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

   Segments

By Type

  • Combination Pills
  • Progestin Pill
  • Monophasic Pills
  • Triphasic Pills
  • Other

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online channel
  • Others

Regional Scope

North America- United States, Canada, and Mexico

Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Contraceptive Pills Market Key Players

  1. Teva Pharmaceuticals
  2. Bayer AG
  3. Pfizer Inc.
  4. Amneal Pharmaceuticals LLC
  5. Mayne Pharma
  6. Abbvie Inc. (Allergan PLC)
  7. Aurobindo Pharma Limited
  8. Organon International (Merck & Co. Inc.)
  9. Novartis AG
  10. GlaxoSmithKline PLC
  11. Zydus Lifesciences Ltd.
  12. Sun Pharmaceutical Industries Ltd.
  13. Church & Dwight Co Inc.
  14. Cipla Inc.
  15. Dr. Reddy's Laboratories Ltd.
  16. Ferring B.V.
  17. Lupin Pharmaceuticals Inc.
  18. Vardhaman Lifecare Pvt. Ltd.
  19. Glenmark Pharmaceuticals
  20. Piramal Enterprises Ltd.
  21. Mankind Pharma Ltd.
  22. Marksans Pharma
  23. Perrigo Company PLC
  24. XXX Ltd.


Frequently Asked Questions

Implications of pregnancy are expected to be the major drivers of the market.

1.    Contraceptive Pills Market: Research Methodology 
2.    Contraceptive Pills Market: Executive Summary
3.    Contraceptive Pills Market: Competitive Landscape

3.1. Stellar Competition Matrix
3.2. Competitive Landscape
3.3. Key Players Benchmarking
3.4. Market Structure
3.4.1.    Market Leaders 
3.4.2.    Market Followers
3.4.3.    Emerging Players

3.5. Consolidation of the Market
4.    Contraceptive Pills Market: Dynamics
4.1. Market Trends 
4.2. Market Drivers 
4.3. Market Restraints
4.4. Market Opportunities
4.5. Market Challenges
4.6. PORTER’s Five Forces Analysis
4.7. PESTLE Analysis
4.8. Strategies for New Entrants to Penetrate the Market
4.9. Regulatory Landscape by Region
4.9.1.    North America
4.9.2.    Europe
4.9.3.    Asia Pacific
4.9.4.    Middle East and Africa
4.9.5.    South America

4.10. Contraceptive Pills Market Size and Forecast by Segments (by Value USD Million)
4.10.1.    Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
4.10.1.1.    Combination Pills
4.10.1.2.    Progestin Pill
4.10.1.3.    Monophasic Pills
4.10.1.4.    Triphasic Pills
4.10.1.5.    Other
4.10.2.    Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
4.10.2.1.    Hospital Pharmacy
4.10.2.2.    Retail Pharmacy
4.10.2.3.    Clinics 
4.10.2.4.    Online channel 
4.10.2.5.    Others
4.10.3.    Contraceptive Pills Market Size and Forecast, by Region (2023-2030)
4.10.3.1.    North America
4.10.3.2.    Europe
4.10.3.3.    Asia Pacific
4.10.3.4.    Middle East and Africa
4.10.3.5.    South America

5.    North America Contraceptive Pills Market Size and Forecast (by Value USD Million)
5.1. North America Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
5.1.1.    Combination Pills
5.1.2.    Progestin Pill
5.1.3.    Monophasic Pills
5.1.4.    Triphasic Pills
5.1.5.    Other

5.2. North America Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
5.2.1.    Hospital Pharmacy
5.2.2.    Retail Pharmacy
5.2.3.    Clinics 
5.2.4.    Online channel 
5.2.5.    Others

5.3. North America Contraceptive Pills Market Size and Forecast, by Country (2023-2030)
5.3.1.    United States
5.3.2.    Canada
5.3.3.    Mexico

6.    Europe Contraceptive Pills Market Size and Forecast (by Value USD Million)
6.1. Europe Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
6.1.1.    Combination Pills
6.1.2.    Progestin Pill
6.1.3.    Monophasic Pills
6.1.4.    Triphasic Pills
6.1.5.    Other

6.2. Europe Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
6.2.1.    Hospital Pharmacy
6.2.2.    Retail Pharmacy
6.2.3.    Clinics 
6.2.4.    Online channel 
6.2.5.    Others

6.3. Europe Contraceptive Pills Market Size and Forecast, by Country (2023-2030)
6.3.1.    UK
6.3.2.    France
6.3.3.    Germany
6.3.4.    Italy
6.3.5.    Spain
6.3.6.    Sweden
6.3.7.    Russia
6.3.8.    Rest of Europe

7.    Asia Pacific Contraceptive Pills Market Size and Forecast (by Value USD Million)
7.1. Asia Pacific Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
7.1.1.    Combination Pills
7.1.2.    Progestin Pill
7.1.3.    Monophasic Pills
7.1.4.    Triphasic Pills
7.1.5.    Other

7.2. Asia Pacific Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
7.2.1.    Hospital Pharmacy
7.2.2.    Retail Pharmacy
7.2.3.    Clinics 
7.2.4.    Online channel 
7.2.5.    Others

7.3. Asia Pacific Contraceptive Pills Market Size and Forecast, by Country (2023-2030)
7.3.1.    China
7.3.2.    S Korea
7.3.3.    Japan
7.3.4.    India
7.3.5.    Australia
7.3.6.    ASEAN
7.3.7.    Rest of Asia Pacific

8.    Middle East and Africa Contraceptive Pills Market Size and Forecast (by Value USD Million)
8.1. Middle East and Africa Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
8.1.1.    Combination Pills
8.1.2.    Progestin Pill
8.1.3.    Monophasic Pills
8.1.4.    Triphasic Pills
8.1.5.    Other

8.2. Middle East and Africa Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
8.2.1.    Hospital Pharmacy
8.2.2.    Retail Pharmacy
8.2.3.    Clinics 
8.2.4.    Online channel 
8.2.5.    Others

8.3. Middle East and Africa Contraceptive Pills Market Size and Forecast, by Country (2023-2030)
8.3.1.    South Africa
8.3.2.    GCC
8.3.3.    Egypt
8.3.4.    Rest of ME&A

9.    South America Contraceptive Pills Market Size and Forecast (by Value USD Million)
9.1. South America Contraceptive Pills Market Size and Forecast, by Type (2023-2030)
9.1.1.    Combination Pills
9.1.2.    Progestin Pill
9.1.3.    Monophasic Pills
9.1.4.    Triphasic Pills
9.1.5.    Other

9.2. South America Contraceptive Pills Market Size and Forecast, by Distribution Channel (2023-2030)
9.2.1.    Hospital Pharmacy
9.2.2.    Retail Pharmacy
9.2.3.    Clinics 
9.2.4.    Online channel 
9.2.5.    Others

9.3. South America Contraceptive Pills Market Size and Forecast, by Country (2023-2030)
9.3.1.    Brazil
9.3.2.    Argentina
9.3.3.    Rest of South America

10.    Company Profile: Key players
10.1. Teva Pharmaceuticals
10.1.1.    Company Overview
10.1.2.    Financial Overview
10.1.3.    Business Portfolio
10.1.4.    SWOT Analysis
10.1.5.    Business Strategy 
10.1.6.    Recent Developments

10.2. Bayer AG
10.3. Pfizer Inc.
10.4. Amneal Pharmaceuticals LLC
10.5. Mayne Pharma
10.6. Abbvie Inc. (Allergan PLC)
10.7. Aurobindo Pharma Limited
10.8. Organon International (Merck & Co. Inc.)
10.9. Novartis AG
10.10. GlaxoSmithKline PLC
10.11. Zydus Lifesciences Ltd.
10.12. Sun Pharmaceutical Industries Ltd.
10.13. Church & Dwight Co Inc.
10.14. Cipla Inc.
10.15. Dr. Reddy's Laboratories Ltd.
10.16. Ferring B.V.
10.17. Lupin Pharmaceuticals Inc.
10.18. Vardhaman Lifecare Pvt. Ltd.
10.19. Glenmark Pharmaceuticals
10.20. Piramal Enterprises Ltd.
10.21. Mankind Pharma Ltd.
10.22. Marksans Pharma
10.23. Perrigo Company PLC
11.    Key Findings
12.    Industry Recommendation

Enquiry Before Buy


Request Sample PDF